[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462972":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":39,"responsibleParty":66,"collaborators":37,"id":68,"slug":37,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":37,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":37,"overallStatus":42,"whyStopped":37,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Post-Transplant-Liver Allograft Fibrosis","ACTIVE_COMPARATOR","Pediatric patients who have undergone liver transplantation , the occurrence of graft fibrosis necessitates hospitalization for biopsy and treatment to assess the degree of fibrosis and its underlying causes.",[13],"Diagnostic Test: Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)",{"label":15,"type":16,"description":17,"interventionNames":18},"Post-Transplant-Liver Allograft regular recovery","SHAM_COMPARATOR","Pediatric patients who have undergone liver transplantation and have recovered normally typically undergo liver biopsy around 3 to 5 years postoperatively and around 10 years postoperatively to evaluate the presence of potential subclinical rejection. This assessment guides the long-term application of immunosuppressive medications.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)","Liver biopsies will be performed at 3 months, 6 months and 12 months post-transplant. Fibrosis was evaluated using the liver allograft fibrosis score (LAFSc) staging system. Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA)or (FBLN3,YKL40,LECT2 etc.)",[9,15],[26],"Liver Allograft Fibrosis by Using Fibrosis Panel(FBLN3,YKL40,LECT2 etc.)",[28],{"name":29,"affiliation":30,"role":31},"Hao FENG","Dept. of Liver surgery, Renji Hospital, Medical School of Shanghai Jiaotong University","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Yi ZHOU","CONTACT","008619921528834",null,"fenghao@renji.com",[40,56],{"facility":41,"status":42,"city":43,"state":37,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","200127","China",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":37,"phoneExt":37,"email":55},"Qiang Xia, MD, PhD","xiaqiang@medmail.com.cn",{"facility":57,"status":58,"city":43,"state":37,"zip":44,"country":45,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","NOT_YET_RECRUITING",{"type":47,"coordinates":60},[49,50],{"lat":50,"lon":49},[63],{"name":64,"role":35,"phone":37,"phoneExt":37,"email":65},"Hao Feng, MD, PhD","surgeonfeng@live.com",{"type":67,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100462972",false,"NCT05308628","Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel","Effect of the Fibrosis Panel on the Evaluation of Allograft Fibrosis After Pediatric Liver Transplantation","PT-LiFE","Inclusion Criteria:\n\n* Male or female participant must be between 8 weeks and 18 years of age.\n* Participant is a recipient of a first liver allograft from cadaveric or living donors.\n* Participant is a single-organ recipient (liver only).\n* Participants' parent\u002Fguardian is capable of understanding the purposes and risks of the study and must sign an informed consent for the study.\n\nExclusion Criteria:\n\n* Participants older than 18 years of age\n* Pregnant or breastfeeding\n* Active systemic infections\n* Receiving any form of solid organ retransplantation\n* Multiorgan transplantation\n* Multi organ failure\n* Congenital sufferers from heart, lung, kidney, nervous system or blood disease\n* Refused to participate the study","ALL","2 Months","18 Years",{"count":79,"type":80},1200,"ESTIMATED","INTERVENTIONAL",[83],"NA","Liver transplantation in children is highly successful with \\>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation (\"idiopathic\" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.",[86,87,88],"Liver Fibrosis","Pediatric Disorder","Liver Transplant; Complications","2024-08-05",{"date":91,"type":92},"2024-08-07","ACTUAL",{"date":94,"type":92},"2022-04-30",{"date":96,"type":80},"2025-11-30",{"name":5,"class":6},2]